This document provides practical guidance to EU/EEA Member States willing to implement a pilot study for the harmonised and coordinated targeted genomic surveillance of SARS-CoV-2 at selected international points of entry (PoE), to complement national and international genomic surveillance.
This document provides operational recommendations regarding the implementation of a set of measures that has been agreed by the Member States in the context of a precautionary approach to potential severe worsening of the COVID-19 epidemiological situation.
This guidance document includes an updated summary of diagnostic PCR and serology together with detailed information on isolation, culture, identification and epidemiological typing of B. pertussis to help users choose the best methods within the local technical and financial provisions.
In order to explore how insights from the implementation of non-pharmaceutical interventions (NPIs) during the COVID-19 pandemic may guide further preparedness for COVID-19 – as well as pandemic preparedness and response work in the EU more generally, ECDC organised an expert consultation in June 2022 on the implementation and evaluation of NPIs. This report summarises the findings from that consultation.
This document aims to provide guidance for public health and laboratory experts in identifying human infections with animal influenza viruses as early as possible to provide early warning and inform risk assessments and public health measures.
This Reporting Protocol contains guidelines on how to prepare data for submission to TESSy, deadlines for data submission, subject-specific information, and links to further information.
This pilot protocol is primarily intended to guide the implementation of a first pilot ECDC-funded study using routinely collected data, and includes a concise overview of the systems of the countries included in the pilot study.
This protocol outlines the methods for a prospective cohort study in long-term care facilities (LTCFs) to evaluate the effectiveness of COVID-19 vaccines in preventing laboratory-confirmed SARS-CoV-2 symptomatic infection in LTCF residents.